FDA Grants Approval for Clinical Data, Inc.’s (CLDA) Viibryd

QualityStocks would like to highlight Clinical Data, Inc. (NASDAQ: CLDA). The company's mission is to develop first-in-class and best-in-category therapeutics. The company is FDA approved to market Viibryd for major depressive disorder in adults and is advancing its late-stage drug candidate, Stedivaze, a pharmacologic stress agent in Phase III development for use in myocardial perfusion imaging. Clinical Data also has promising drug candidates entering the clinic in major therapeutic areas including asthma, ophthalmology and diabetes.

In the company’s news yesterday,

Clinical Data, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets to be marketed under the brand name Viibryd™. A new molecular entity and the first and only selective serotonin reuptake inhibitor and 5HT1A receptor partial agonist, Viibryd will be used to treat adults with major depressive disorder (MDD). The company plans to make Viibryd available in U.S. pharmacies before June 30th of this year.

“When treating MDD, our goal is to offer treatment options that meet the individual needs of each patient,” stated Stephen M. Stahl, M.D., Ph.D., Professor of Psychiatry, University of California, San Diego. “Viibryd is an important new treatment option with proven efficacy and a demonstrated safety profile.”

The efficacy of Viibryd as a treatment for MDD was established in two 8-week, multicenter, randomized, double-blind, placebo-controlled studies in adults who met the specified criteria. In these studies, patients were titrated over two weeks to a dose of 40 mg of Viibryd once daily. Viibryd was superior to placebo in the improvement of depressive symptoms as measured by the mean change from baseline to week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score.

“While there are currently available treatments for MDD, no one therapy works for every patient and side effect profiles vary, which may impact both compliance and treatment success,” commented Carol R. Reed M.D., Executive Vice President and Chief Medical Officer of Clinical Data. “Viibryd will be a new choice for healthcare providers and their patients who are suffering from depression.”

“Viibryd is the only antidepressant that is a selective serotonin reuptake inhibitor and 5HT1A receptor partial agonist,” concluded Drew Fromkin, President and CEO of Clinical Data. “It is also the first drug that the Company has developed, and to have received marketing approval from the FDA on its first review is a significant milestone for Clinical Data.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.